Project Grant R03CA289058
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $151K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The University of North Carolina at Charlotte received a $544,712 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to investigate the role of the DNA repair factor REV7 in regulating the tumor suppressor p53. The research aims to determine how REV7 destabilizes p53 in the presence and absence of DNA damage, as well as how REV7 regulates p53 activity. This project summary indicates that the research could provide new insights into the...
- The U.S. National Cancer Institute awarded a $855,249 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports DFCI's research to develop new approaches for targeting cell cycle proteins as potential cancer treatments. The key focus is on investigating how abnormal activation of cyclin-dependent kinases (CDKs) drives uncontrolled tumor cell proliferation, and exploring strategies to overcome limitations of...
- This federal Project Grant award of $627,676 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research at the University of North Carolina at Chapel Hill (UNC-CH) to develop and test novel biosensors for measuring the depth of cell cycle quiescence in cancer cells. The goal is to better understand how different states of quiescence, from shallow to deep, relate to tumor progression and treatment resistance. The 3-year project will define...
- The University of North Carolina at Chapel Hill received a $159,540 Project Grant award from the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports a research project titled "Mechanistic Examination and Inhibitor Targeting of Nutrient Scavenging for the Treatment of Pancreatic Cancer." The project aims to investigate the role of macropinocytosis and autophagy, two metabolic processes that cancer cells use to obtain...
- This Project Grant award of $342,569 was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of North Carolina at Charlotte (UNC Charlotte) to conduct research on the roles and regulations of the APE1 protein in ATR signaling pathways. The key objectives of this 5-year project are to elucidate the mechanisms by which APE1 forms liquid-liquid phase separations in vitro and in the nucleoli of cancer cells, and how this promotes ATR...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,541,280.00 to the University of North Carolina at Chapel Hill to conduct research for "The Breast Cancer Cellular Atlas" project. The award period runs from March 1, 2025 to February 28, 2029. As a prominent public research university, UNC-Chapel Hill specializes in advanced scientific investigations, clinical studies, and...
- This Cooperative Agreement award for $639,882, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at the University of North Carolina at Chapel Hill to elucidate the molecular mechanisms of metastasis organ tropism in breast cancer. The key objectives are to: Identify molecular determinants of lung and liver organ-specific metastasis using a comprehensive dataset of human primary tumors and metastases, as well as genetically...
- The National Cancer Institute awarded a $197,747 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of North Carolina at Chapel Hill. The grant, titled "IMPROVING AFFORDABILITY IN CANCER CARE THROUGH ECONOMIC SCREENING AND SUPPORT (I-ACCESS)", aims to pilot and refine a screening assessment and referral program to proactively identify cancer-related financial hardship in patients and connect them with financial education, counseling, and resources....
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This federal Project Grant award of $680,598 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to understand the role of the Cullin-5 complex in regulating T cell dysfunction in cancer. The research aims to develop new therapeutic approaches to engineer T cells with durable effector function, by targeting the Cullin-5 complex to prevent T cell dysfunction caused by chronic tumor antigen stimulation. The award was provided to the...